Kodiak Sciences Inc.

NASDAQ:KOD

Biotechnology

Healthcare
$97.81 -0.08%

-$0.03 today

Market cap
$6.40B
Beta
2.21
P/E (TTM)
-9.6
EPS (TTM)
-$3.73
52W Low $3.43High $47.84

Volume 0.74M

Average 1.10M

KOD Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Kodiak Sciences Inc.NASDAQ: KOD

Total Equity · Q3 FY2026 · quarter ended Sep 2026

Total equity falls 46.9% from a year ago

Total equity stood at $12.57M at the end of Q3 FY2026, down 46.9% from a year earlier and down 79.4% from the prior quarter. Over 3 fiscal years it compounded at -28.8% a year.

Context

  • Total equity amounted to 6.0% of total assets at the end of Q3 FY2026, down 4.9 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -46.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$12.57M-79.4% QoQ
Last fiscal yearDec 2025
$157.38M+4.7% YoY
Year agoSep 2025
$23.69M-46.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.9%——
1 year+4.7%——
3-year CAGR-28.8%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
157.38M USD
Year-over-year change
+4.7%
4-year CAGR
-30.2%

Total Equity vs competitors

How KOD compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -46.9% is the 9th highest of 10, against a peer median of +5.9%.
  • Total equity amounts to 6.0% of total assets for KOD, versus a peer median of 80.0%.
KOD Competitors
Total Equity for KOD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
REGNRegeneron Pharmaceuticals, Inc.Jun 2026$31.71B USD+5.9%+11.3%76.0%
BLCOBausch + Lomb CorporationJun 2026$6.44B USD-1.0%-2.8%46.5%
BLTEBelite Bio, IncJun 2026$776.64M USD+418.2%+164.8%98.1%
OCULOcular Therapeutix, Inc.Mar 2026$581.57M USD+118.7%+164.5%79.4%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$451.84M USD-3.8%+29.8%88.1%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$230.47M USD-22.8%+47.0%80.0%
OCSOculis Holding AGMar 2026CHF 196.06M CHF+20.6%—80.6%
KODKodiak Sciences Inc.Sep 2026$12.57M USD-46.9%-28.8%6.0%
OCGNOcugen, Inc.Mar 2026$5.81M USD-63.5%—10.2%
OTLKOutlook Therapeutics, Inc.Mar 2026-$28.99M USD+10.7%—132.4%
Peer median (excluding KOD) —+5.9%+38.4%80.0%

Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents731.51M190.43M285.51M168.07M209.86M
Short-term Investments0288.5M000
Net Receivables00000
Inventory00000
Other Current Assets3.3M7.07M3.8M3.86M4.95M
Total Current Assets734.81M486.01M289.31M171.94M214.82M
Property, Plant & Equipment (Net)108.07M115.75M175.02M148.73M121.86M
Goodwill00000
Intangible Assets00000
Long-term Investments6.32M6.32M6.32M6.18M6.18M
Tax Assets00000
Other Non-current Assets55.01M58.55M8.72M8.73M8.67M
Total Non-current Assets169.41M180.62M190.06M163.64M136.72M
Total Assets904.22M666.63M479.37M335.58M351.53M
Account Payables12.43M9.13M13.61M3.92M12.86M
Short-term Debt3.93M9.93M9.77M012.06M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities42.13M27.41M12.27M012.84M
Total Current Liabilities64.68M52.5M41.73M25.57M45.53M
Long-term Debt99.94M100M100M0100M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities211K162K0100M1.5M
Total Non-current Liabilities176.22M177.97M171.86M159.72M148.62M
Total Liabilities240.9M230.46M213.59M185.29M194.15M
Common Stock5K5K5K5K6K
Retained Earnings(558.22M)(892.04M)(1.15B)(1.33B)(1.56B)
Accumulated OCI0(1.31M)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity663.32M436.17M265.78M150.29M157.38M
Total Debt179.94M187.73M181.63M70.35M159.18M
Net Debt(551.57M)(2.7M)(103.88M)(97.73M)(50.68M)

Kodiak Sciences Inc.

NASDAQ:KOD

Intrinsic Alpha fair value

Locked

Current Price

$97.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.